We hypothesized our novel finding of down-regulated AR and AR-V expression following JQ1 treatment represented an important component of the JQ1 anti-AR mechanism of action, reminiscent of down-regulated MYC expression in multiple myeloma cells (50,51). Here, AR is linked to plasma cell myeloma.